Cargando…
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
BACKGROUND: (18)F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with early...
Autores principales: | van Heek, Lutz, Stuka, Colin, Kaul, Helen, Müller, Horst, Mettler, Jasmin, Hitz, Felicitas, Baues, Christian, Fuchs, Michael, Borchmann, Peter, Engert, Andreas, Dietlein, Markus, Voltin, Conrad-Amadeus, Kobe, Carsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206242/ https://www.ncbi.nlm.nih.gov/pubmed/35717166 http://dx.doi.org/10.1186/s12885-022-09758-z |
Ejemplares similares
-
P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
por: Van Heek, Lutz, et al.
Publicado: (2022) -
P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2022) -
FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma—An Updated Overview
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2020) -
T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
por: Eichenauer, Dennis A., et al.
Publicado: (2022) -
P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial
por: Bröckelmann, Paul J., et al.
Publicado: (2022)